Ignite Creation Date:
2024-05-06 @ 10:46 AM
Last Modification Date:
2024-10-26 @ 12:35 PM
Study NCT ID:
NCT03346603
Status:
COMPLETED
Last Update Posted:
2021-07-08
First Post:
2017-11-15
Brief Title:
Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs
Sponsor:
Olive View-UCLA Education Research Institute
Organization:
Olive View-UCLA Education Research Institute
Study Overview
Official Title:
Prevalence of Extended Spectrum β-lactamase and Carbapenem-Resistant Gram-Negative Bacteria in Patients With Urinary Tract Infection and Urosepsis Admitted Through Emergency Departments in the United States
Status:
COMPLETED
Status Verified Date:
2021-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Between 2013-2014 our study network of US emergency departments EMERGEncy ID NET found that the rate of fluoroquinolone-resistant E coli was 117 among all patients 63 in uncomplicated and 199 in complicated ESBL-producing Enterobacteriaceae were found in 77 of all cases 26 in uncomplicated and 122 in complicated More recently Enterobactericeae and gram-negative non fermenting bacteria have started to show resistance to carbapenems CREs and CR-NF Patients hospitalized with UTI and urosepsis represent a higher risk population for infections due to multi-drug resistant bacteria and experience serious adverse outcomes including death EMERGEncy ID NET will conduct a study to determine the prevalence of ESBL-producing CREs and CR-NFs among this high risk population of patients admitted for UTI from US emergency departments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None